• Explore /
  • Poster
  • / A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors.

A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors.

Abstract Video & Slides Poster

Authors

null

Angela Tatiana Alistar

Atlantic Health System, Morristown, NJ

Angela Tatiana Alistar , Anthony B. El-Khoueiry , Devalingam Mahalingam , Monica M. Mita , Hwankyu Kang , Yeong-In Yang , Jiye Ahn , Jeongjun Kim , Baejung Choi , Yeejin Jeon , Chunwon Jung , Borami Jeon , Jaeseung Kim , Kiyean Nam

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2021 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Developmental Therapeutics—Immunotherapy

Track

Developmental Therapeutics—Immunotherapy

Sub Track

New Targets and New Technologies (IO)

Clinical Trial Registration Number

NCT04648254

Citation

J Clin Oncol 39, 2021 (suppl 15; abstr TPS2673)

DOI

10.1200/JCO.2021.39.15_suppl.TPS2673

Abstract #

TPS2673

Poster Bd #

Online Only

Abstract Disclosures

Similar Posters

First Author: Vivek Subbiah

First Author: Funda Meric-Bernstam

First Author: Tomoko Hirohashi

First Author: Jessica Dreger McDermott